Buserelin is a gonadotropin releasing hormoneagonist (GnRH agonist). By causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction. Gonadotropins are protein hormones secreted by gonadotrope cells of the pituitary gland of vertebrates. ... A hormone (from Greek horman - to set in motion) is a chemical messenger from one cell (or group of cells) to another. ... Agonists An agonist is a substance that binds to a receptor and triggers a response by the cell. ... Luteinizing hormone (LH) is a hormone synthesised and secreted by gonadotropes in the anterior lobe of the pituitary gland. ... Follicle stimulating hormone (FSH) is a hormone produced by gonadotropes in the anterior pituitary gland. ... Prostate cancer is a group of cancerous cells (a malignant tumor) that begins most often in the outer part of the prostate. ... Breast cancer is cancer of breast tissue. ... Uterine fibroids (leiomyomata, singular leiomyoma) are the most common neoplasm in females, and may affect about of 25 % of white and 50% of black women during the reproductive years. ... Reproductive technology is a term for all current and anticipated uses of technology in human and animal reproduction, including: artificial insemination artificial wombs cloning (see human cloning for the special case of human beings) cryopreservation of sperm, oocytes, embryos embryo testing embryo transfer genetic engineering hormone treatment to increase fertility...
It is normally delivered via a nasal spray but is also available as an injection.
Buserelin acetate is marketed by Sanofi-Aventis under the brand name Suprefact. Sanofi-Aventis (Euronext:FR0000120578) (NYSE:SNY), headquartered in Paris, France, is the worlds number 3 company in the pharmaceutical industry (behind Pfizer and GlaxoSmithKline, but above Merck and AstraZeneca). ...
Suprefact depot (Buserelin) is used for the treatment of prostate cancer.
Women using buserelin for treatment of endometriosis usually use the buserelin nasal solution at a dose of 400 µg (two sprays into each nostril) three times daily.
For men using buserelin for long-term control of prostate cancer, a long-lasting buserelin implant (called a "depot") can be implanted under the skin into the abdominal wall by the doctor every two months.
Feeds |
Contact